Pfizer/Astellas’ Xtandi cuts risk of prostate cancer spread
Adding Pfizer and Astellas Pharma’s Xtandi to hormone therapy significantly cut the risk of prostate cancer spreading compared to hormone therapy alone, trial findings show.
6th February 2018